Mode
Text Size
Log in / Sign up
Phase 1 Completed N=90 Randomized Quadruple-blind Treatment

Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects

Acanthamoeba Keratitis
Source: ClinicalTrials.gov NCT02506257 ↗
Enrolled (actual)
90
Serious AEs
0.0%
Results posted
Nov 2016
Primary outcomePrimary: Number of Subjects With Dose-limiting Adverse Events — 0; 2; 3; 0 participants

Summary

Randomized, double-masked, placebo-controlled, multiple center, parallel-group Phase 1 study to evaluate the safety and tolerability of 3 doses of preservative-free PHMB ophthalmic solution compared to placebo in healthy subjects

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Subjects With Dose-limiting Adverse Events
0; 2; 3; 0
SECONDARY
Plasma Concentration of PHMB
0; 0; 0; 0

Eligibility Criteria

Inclusion Criteria

  • able and willing to give informed consent.
  • man or woman of any race and 18 to 55 years of age, inclusive.
  • Body Mass Index of 20-30 kg/m2
  • willing and able to attend required study visits.
  • bilateral visual acuity >6/10.
  • intraocular pressure (IOP) of 14-21 mmHg.
  • ophthalmologic examination without abnormalities.
  • medical history without major pathology.
  • laboratory test results without deviations from the normal range.
  • female subjects of childbearing potential with negative urine pregnancy test and using effective contraception during the study.

Exclusion Criteria

  • presence of bacterial ocular infections.
  • presence of any concomitant ocular pathology.
  • performing activities likely to result in an irritated conjunctiva during the study (including heavy alcohol intake, swimming in chlorinated water and heavy smoking).
  • contact lenses wearing .
  • ocular surface fluorescein staining score >3.
  • use of topical or systemic antibiotics, antihistamines, decongestants and non-steroidal anti-inflammatory agents as well as steroids within 7 days before screening.
  • known or suspected allergy to biguanides or intolerance to any other ingredient of the test treatments.
  • ocular surgery performed within 12 months before screening.
  • participation in another clinical study in the preceding 30 days.
  • one functional eye.
  • pregnancy or breastfeeding.
  • use of recreational drugs.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02506257). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search